ClinicalTrials.gg
CompletedNCT00049998Updated Mar 4, 2013

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

A Phase 3 interventional study of topotecan in Non-Small-Cell Lung Cancer, sponsored by GlaxoSmithKline. Completed at 114 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
2nd of 47
760 · median 88
Started
2001
the only one that year
Phase 3
7 of 54
1 open now
Registered
2nd of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2001, is one of 7 in phase 3, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).

03

Conditions studied

  • Non-Small-Cell Lung Cancer

Keywords

  • Nonsmall Cell Lung cancer
  • advanced
  • Second-line
  • topotecan
  • Hycamtin
  • oral
  • docetaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Patients with advanced non-small cell lung cancer (NSCLC).
  • Patients who have received one previous chemotherapy for NSCLC.
  • Full recovery from previous chemotherapy.
  • Presence of either measurable or non- by radiologic study or physical examination.
  • At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient).
  • At least 24 hours since prior radiotherapy providing that marked bone marrow suppression is NOT expected. Patients who have received radiotherapy must have recovered from any reversible side effects (e.g. nausea and vomiting).
  • Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.

Exclusion criteria

Exclusion Criteria:

  • Symptoms of (cancer spreading to the brain), requiring treatment with .
  • Active infection.
  • Severe medical problems other than the diagnosis of NSCLC, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk.
  • Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or therapy for the treatment of NSCLC.
  • Use of investigational drug within 30 days prior to the first dose of study medication.
  • Women who are pregnant or lactating.
  • Patients of refusing to practice adequate methods.
  • Patients with conditions which might alter absorption of an oral drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
760 participants

Interventions

06

What researchers measure

Primary outcomes

  1. One-year survival rate

Secondary outcomes

  1. overall survival, time to progression, response rate, response duration, time to response, improvement in quality of life and patient well-being, and qualitative and quantitative toxicities.

07

Study locations

114 sites
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Bedford Park, South Australia 5042, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
  • GSK Investigational Site
    Ringwood East, Victoria 3128, Australia
  • GSK Investigational Site
    Innsbruck, A-6020, Austria
  • GSK Investigational Site
    Sankt Pölten, A-3100, Austria
  • GSK Investigational Site
    Vienna, A-1220, Austria
  • GSK Investigational Site
    Braasschaat, 2930, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Sydney, Nova Scotia B1P 1P3, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1G 2B9, Canada
  • GSK Investigational Site
    Thunder Bay, Ontario P7B 6V4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Toronto, Ontario M6S 1B5, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Montreal, Quebec H3A 1A1, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • GSK Investigational Site
    Xi'an, Shaanxi 710061, China
  • GSK Investigational Site
    Beijing, 100036, China
  • GSK Investigational Site
    Shanghai, 200433, China
  • GSK Investigational Site
    Shanghai, China
  • GSK Investigational Site
    Tianjin, China
  • GSK Investigational Site
    Wangfujing, Beijing, 100730, China
  • GSK Investigational Site
    České Budějovice, 370 87, Czechia
  • GSK Investigational Site
    Kladno, 140 59, Czechia
  • GSK Investigational Site
    Prague, 14059, Czechia
  • GSK Investigational Site
    Herlev, Denmark
  • GSK Investigational Site
    Odense C, DK-5000, Denmark
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Caen, 14076, France
  • GSK Investigational Site
    Dijon, 21079, France
  • GSK Investigational Site
    Strasbourg, 67098, France
  • GSK Investigational Site
    Toulon Naval, 83800, France
  • GSK Investigational Site
    Vesoul, 70014, France
  • GSK Investigational Site
    Gauting, Bavaria 82131, Germany
  • GSK Investigational Site
    Munich, Bavaria 80336, Germany
  • GSK Investigational Site
    Regensburg, Bavaria 93049, Germany
  • GSK Investigational Site
    Treuenbrietzen, Brandenburg 14929, Germany
  • GSK Investigational Site
    Hamburg, Free and Hanseatic City of Hamburg 21075, Germany
  • GSK Investigational Site
    Leipzig, Saxony 04207, Germany
  • GSK Investigational Site
    Berlin, State of Berlin 14109, Germany
  • GSK Investigational Site
    Bad Berka, Thuringia 99437, Germany
  • GSK Investigational Site
    Athens, 11526, Greece
  • GSK Investigational Site
    Heraklion, Crete, 71110, Greece
  • GSK Investigational Site
    Papagos, Athens, 15669, Greece
  • GSK Investigational Site
    Rio, Patras, 265 00, Greece
  • GSK Investigational Site
    Thessaloniki, 54007, Greece
  • GSK Investigational Site
    Budapest, 1529, Hungary
  • GSK Investigational Site
    Csorna, 9300, Hungary
  • GSK Investigational Site
    Miskolc, 3529, Hungary
  • GSK Investigational Site
    Ashkelon, 78306, Israel
  • GSK Investigational Site
    Beersheba, 84101, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Rome, Lazio 00149, Italy
  • GSK Investigational Site
    Turin, Piedmont 10126, Italy
  • GSK Investigational Site
    Sassari, Sardinia 07100, Italy
  • GSK Investigational Site
    Perugia, Umbria 06122, Italy
  • GSK Investigational Site
    Verona, Veneto 37135, Italy
  • GSK Investigational Site
    Riga, LV 1002, Latvia
  • GSK Investigational Site
    Riga, LV 1079, Latvia
  • GSK Investigational Site
    Kaunas, LT-50009, Lithuania
  • GSK Investigational Site
    Vilnius, LT-08660, Lithuania
  • GSK Investigational Site
    's-Hertogenbosch, 5211 NL, Netherlands
  • GSK Investigational Site
    Delft, 2625 AD, Netherlands
  • GSK Investigational Site
    Groningen, 9721 SW, Netherlands
  • GSK Investigational Site
    Heerlen, 6419 PC, Netherlands
  • GSK Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • GSK Investigational Site
    Newtown, Wellington, 6002, New Zealand
  • GSK Investigational Site
    Quezon City, 1100, Philippines
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Warsaw, 02-781, Poland
  • GSK Investigational Site
    Lisbon, 1769-166, Portugal
  • GSK Investigational Site
    Porto, 4200-319, Portugal
  • GSK Investigational Site
    Moscow, 115 478, Russia
  • GSK Investigational Site
    Moscow, 117 837, Russia
  • GSK Investigational Site
    Moscow, 129 128, Russia
  • GSK Investigational Site
    Nizhny Novgorod, 603 000, Russia
  • GSK Investigational Site
    Saint Petersburg, 198255, Russia
  • GSK Investigational Site
    Samara, 443066, Russia
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Pretoria, Gauteng, South Africa
  • GSK Investigational Site
    Cape Town, Western Province, South Africa
  • GSK Investigational Site
    Port Elizabeth, 6001, South Africa
  • GSK Investigational Site
    Barakaldo (Vizcaya), 48903, Spain
  • GSK Investigational Site
    Jaén, 23007, Spain
  • GSK Investigational Site
    La Laguna (Santa Cruz de Tenerife), 38320, Spain
  • GSK Investigational Site
    Lleida, 25198, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28047, Spain
  • GSK Investigational Site
    Málaga, 29020, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07014, Spain
  • GSK Investigational Site
    Pontevedra, 36002, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain
  • GSK Investigational Site
    Zurich, CH-8091, Switzerland
  • GSK Investigational Site
    Taipei, 100, Taiwan

Showing the first 100 of 114 sites across 31 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001 and a primary completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2002
First posted
Nov 20, 2002
Start
Oct 2001
Primary completionActual
Apr 2004
Last update
Mar 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00049998
Lead sponsor
GlaxoSmithKline
First posted
Nov 20, 2002
Start date
Oct 2001
Primary completion
Apr 2004
Last update
Mar 4, 2013

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion